Estriol entered scientific conversation back in the early 20th century during a period when researchers were still untangling the complicated world of hormones. Folks recognized early on that among the three major estrogens produced in the human body—estrone, estradiol, and estriol—estriol took a different path. Mostly, it turned up in high amounts during pregnancy. By the 1960s and 1970s, pharmaceutical companies were regularly isolating and refining estriol to serve medical needs, driven by growing interest in hormone therapy as women searched for menopause symptom relief without some of the risks tied to stronger estrogens. Today, estriol carries its own niche in hormone replacement therapy and urogenital atrophy management, especially in parts of Europe and Asia.
Estriol arrives as a white, odorless crystalline solid that dissolves a bit in alcohol and much less so in water. Its structure is more similar to estradiol than estrone, but it carries three hydroxyl groups, which shifts its behavior in the body and in the lab. The molecular formula is C18H24O3, with a weight tipping the scales at just over 288 g/mol. These extra hydroxyl groups mean estriol breaks down quicker in the liver, so it doesn’t hang around as long as other estrogens—offering a milder, shorter-lived hormonal effect. Talking about melting points, estriol begins to melt at around 280°C, which puts it on par with related compounds. It doesn’t really pack strong odors or taste, which might not seem important, but no pharmacist wants a medicine that patients have to choke down.
Pharmacies label estriol products by strict concentration guidelines. Oral tablets can range from 0.5 mg to 2 mg per dose, while creams carry concentrations anywhere from 0.01% to 0.1%. Packaging includes expiry dates, batch numbers, and clear dosing instructions. Each batch has to clear purity standards—no more than a trace of related impurities allowed. Pharmacopeial monographs give the details: purity percent, particle size distribution, moisture content, and microbial contamination limits. Suppliers often include data sheets showing chromatographic purity, which, in real terms, means labs confirm the estriol hasn’t broken down or picked up unwanted chemical cousins along the way.
Manufacturers usually go the route of chemical synthesis, starting with plant sterols like diosgenin or stigmasterol harvested from yams, soybeans, or other common crops. Chemists turn these raw materials into intermediates—think estrone or estradiol—before introducing extra hydroxyl groups using controlled oxidation and reduction steps. The process calls for precise temperature and pH control, a lifetime supply of solvents, and highly trained operators who learn from years of lab work how to coax the right reactions out of stubborn molecules. After that, purification takes over. Most drug manufacturers run estriol through column chromatography, constantly testing each batch for trace contamination.
Estriol’s structure leaves it open to several lab tweaks. Chemists can esterify the hydroxyl groups to produce prodrugs like estriol succinate or estriol acetate. These esters open doors for specialty dosing—some dissolve badly in water but absorb well through skin, lending themselves to creams and gels. Under acidic conditions, estriol can undergo dehydration reactions, although most pharmaceutical labs steer well away from those to avoid unwanted byproducts. Over-oxidation produces compounds with little physiological activity, which limits the range of changes a drug maker finds useful. This chemical flexibility, paired with short metabolic half-life, sets estriol apart as a hormone that’s easier to fine-tune for temporary therapeutic effects.
In the pharmacy, estriol wears a few different hats. Chemists code it as “E3” in academic papers. On packaging, you’ll see names like Ovestin (Europe), Gynest, or E3 Cream. Older literature sometimes records it under names such as tri-hydroxyestrin, 16α-hydroxyestradiol, or “oestriol” (using British spelling rules). These alternate names crop up for a reason: researchers publishing work in multiple languages or across national boundaries often pick the version familiar to local prescribers. Patients rarely notice these differences, but clinicians and pharmacists have to keep a running mental catalog to avoid mistakes in dosing or product selection.
Pharmaceutical makers follow Good Manufacturing Practice (GMP) standards when preparing estriol products. This isn’t a box-checking exercise—one bad batch could mean a wave of product withdrawals or patient complaints about skin reactions or unusual bleeding. Workers in the lab wear gloves, masks, and clean-room suits; tablets and creams get sealed by automated machines under negative pressure. Regulators enforce strict limits on solvent residue, heavy metals, and microbial counts. Speaking from experience, even small deviations from these standards lead to more regulatory audits, wasted product, and stressed-out employees. Like most hormones, estriol must stay locked away from kids, pets, and uninformed handlers. Storage conditions call for cool, dry environments—heat and humidity mean faster breakdown and lost potency.
Doctors commonly prescribe estriol in hormone replacement therapy, especially for menopause symptoms like vaginal dryness, itching, and pain during intercourse. Localized estriol creams or pessaries usually target urogenital atrophy because its weaker effect doesn’t trigger significant changes throughout the rest of the body. In some European clinics, estriol therapy has been explored in managing multiple sclerosis relapses and other autoimmune conditions, although that’s not standard practice everywhere. Unlike higher-potency estrogens, estriol’s shorter activity window and rapid clearance offer reassurance for risk-averse patients and physicians. In real-world settings, this means people who need symptom relief but want to dodge long-term hormone exposure lean more toward estriol.
Estriol attracts ongoing research interest as a “gentler” alternative to estradiol or synthetic estrogens. Scientists regularly publish findings about its unique action profile—low potency, rapid breakdown, and selective receptor affinity. Teams at universities explore whether estriol might protect the brain or immune system in ways unrelated to conventional hormone therapies. Some research groups run clinical trials for estriol as an adjunct therapy for women with unexplained infertility and recurrent miscarriage. Lab workers use high-throughput screening and molecular docking studies to design new estriol esters or delivery systems, hoping to boost tissue targeting without raising systemic risks. The hope is to widen the variety of safe, user-friendly hormone therapies for an aging population.
Despite its weaker profile, estriol hasn’t escaped toxicity screening. Animal studies show that high doses result in classic estrogenic side effects, such as increased uterine weight and cell proliferation, though the effects fade quickly once the drug clears the system. Human case studies chart mostly mild adverse events—headaches, mild breast tenderness, occasional spotting. Cancers tied to strong estrogens appear less frequently with estriol, according to long-term epidemiological work in Scandinavian countries, but researchers keep watchful eyes on rare outcomes like thromboembolism. Specialists urge caution among patients with existing hormone-sensitive cancers or those at high risk. Compared with older generations of hormone therapy, estriol comes out as a lighter touch, but thorough evaluation goes on, especially for long-term users or those with layered health conditions.
Scientists and pharmaceutical teams look toward fine-tuning estriol for new applications. Drug delivery systems—patches, microspheres, vaginal rings—could bring steadier and more localized hormone uptake, possibly lowering side effects even further. Clinics and patient advocates push for expanded real-world data collection, seeking to pin down which user groups benefit most from estriol therapy and who should avoid it altogether. Some researchers test combinations with other drugs, including low-dose progestogens or non-hormonal compounds, to broaden applicability for symptom management in menopause, autoimmune disorders, or fertility support. Regulatory agencies in Asia and Europe might reevaluate safety labels as stronger evidence arrives. Practical use may drift further from one-size-fits-all therapy, as patients and clinicians demand custom options with clearer safety signals and less disruption to daily life. Looking at all the ongoing studies and patient experiences, this mild but versatile estrogen stands ready to claim an even broader share of hormone therapy in the coming decades.
Estriol holds a unique place among estrogens. Unlike its counterparts—estradiol and estrone—estriol often gets overlooked, yet many women depend on it. Estriol peaks during pregnancy, but it surfaces as a critical player in hormone replacement, too. I learned about its value when my aunt started menopause treatment. Her gynecologist explained how gentler options like estriol can offer symptom relief, especially for dryness and irritation, without the same risks as stronger estrogens.
Doctors often turn to estriol for women struggling with menopausal symptoms. Vaginal dryness, irritation, and urinary troubles hit many women hard—which can ripple into relationships and self-confidence. Topical estriol cream often creates real relief for these issues. Unlike systemic estrogens, topical estriol offers targeted help, and research suggests it rarely spikes cancer risk the way high-dose therapies might. That kind of information can give women some peace of mind, especially after so much news about hormone therapy risks over the last two decades.
Stronger estrogens carry well-documented risks like blood clots or cancer in certain women. Estriol’s weaker profile means it lets doctors fine-tune dosing, lowering the chance of side effects. I’ve seen friends try several options before landing on estriol, grateful for a way to sleep through the night without hot flashes flaring up. Some studies show estriol can even improve urinary incontinence, which tends to get ignored, though it wrecks daily life for millions.
Estriol’s use isn’t limited to menopause. It often helps women during recovery from pelvic surgeries or after cancer treatments that disrupt hormone levels. After my neighbor’s radiation treatment for cervical cancer, she struggled with pain from tissue thinning. Her oncologist recommended an estriol vaginal gel, which, after a few weeks, helped her take walks again without discomfort. In those moments, quality of life means more than academic debate about estrogen strength.
Every treatment brings its own set of pros and cons. Estriol isn’t entirely free from side effects—few medicines are. With estriol, doctors worry less about systemic absorption, so the likelihood of major complications drops way down. It’s not always the simple answer; not all pharmacies stock it, and some insurance plans won’t pay for compounded creams. It still demands a prescription. But being able to tackle a symptom at its source, with minimal risk, marks a real step forward.
Clinicians lean on professional guidelines. The North American Menopause Society points to estriol as a reasonable pick for women fearing systemic side effects. That said, ongoing research matters. Long-term trials should produce more detail on who benefits most, and which delivery method gets results with the fewest complications. We need more voices at the table—patients, researchers, and advocates—sharing what works, so treatment gets better with each new year.
Estriol’s story reflects how medicine keeps evolving. Listening to patients and blending real experience with good research helps turn once-overlooked treatments into daily essentials. For millions managing menopause or healing from cancer, tailored solutions mean getting back to living fully.
Estriol stands out as one of the gentler forms of estrogen, a hormone that plays a big role in women’s well-being, especially after menopause. Some prescribe it to address vaginal dryness, discomfort during intimacy, and even bladder symptoms. The basics sound simple, but many women wonder how to make sure they use estriol right—whether it’s cream or oral tablets. Too often, I’ve met women in clinics who feel at a loss over the best routine, or who begin treatment without clear guidance.
I hear a lot of confusion about doses and timing. For local symptoms like dryness or pain, doctors often suggest applying a small, pea-sized amount of cream inside the vagina. This might be every evening at first, usually for a couple of weeks. As comfort returns, some switch to a lower maintenance schedule, like two nights each week. Applying at night helps because staying still lets the medicine soak in—otherwise it tends to leak out a bit. Gently wash hands before and after, use the applicator if one comes with the prescription, and take your time. A little goes a long way, and it’s better to use only the amount directed. If anything feels irritating, tell your doctor right away.
Tablets work differently. Taken by mouth, they affect the whole body, not just one area. These carry bigger benefits for some symptoms, but they bring extra risks as well, such as blood clots or breast tenderness. Swallow tablets with water at the same time each day so the hormone levels stay even. If you miss a dose or forget for a day, don’t double up. Just get back on track the next day. Keep up with regular check-ups and screenings—especially mammograms and pelvic exams. If you see blood after menopause, schedule an appointment as soon as possible, as doctors stress that postmenopausal bleeding always needs checking out.
There’s a reason health authorities in Europe and North America set clear advice about hormone therapy. Every woman’s story brings unique concerns. Low estrogen affects quality of life, but too much carries its own risks. Doctors weigh things like your age, family history, and whether you’ve had breast cancer or blood clots before. The North American Menopause Society supports vaginal estriol for women bothered by dryness or discomfort, finding it safe and effective for most who can’t or don’t want stronger hormone options. Still, it’s not for everyone, so open and ongoing conversations with your healthcare team always matter.
Not every pharmacy gets dosing right. The tablet and cream strengths vary by brand. Following the printed instructions and consulting with experienced pharmacists can reduce worries. Fact sheets from trusted health agencies like the FDA or NHS help people avoid fake products and spot side effects early. Some women ask about lifestyle changes, and while exercise, nutrition, and stress relief all offer value, hormonal dryness and pain usually need more than home remedies.
Keeping track of changes—both positive and negative—helps doctors adjust treatment safely. Always finish medicine courses as agreed, and check in with your doctor if you notice soreness, discharge, or unexpected bleeding. If you switch from cream to tablets or vice versa, mention it at appointments so all your records line up. Estriol, used carefully, truly can improve daily life by easing discomfort and restoring confidence.
Estriol grabs attention mainly in hormone replacement therapy for women, especially during and after menopause. Some doctors see it as a gentler estrogen compared to estradiol. People choose it hoping for fewer risks, particularly when worried about breast cancer or blood clots. Even so, it’s wise to remember that every hormone, even mild ones, can carry side effects.
People taking estriol may face things they’d expected from hormone changes. Swelling in hands, feet, or face sometimes shows up. Headaches or breast tenderness can pop in and out. Some people notice an uptick in weight or see their skin break out. These side effects often fade with time, but they still make daily life less comfortable.
Some physical symptoms catch people off guard. Vaginal spotting or changes in monthly bleeding patterns may raise concern. Sometimes nausea or an upset stomach sets in. Mood swings follow close behind. Hormones can push feelings up or down, bringing out tears, irritation, and even spells of anxiety. Sleep suffers for some, leading to tired mornings and fuzzy thinking.
Every medication carries rare but important warnings. Estriol stands no different. Unusual leg pain, swelling, chest pain, or shortness of breath need attention right away, since these point to possible blood clots. Though studies hint lower risk compared to stronger estrogens, the chance isn’t wiped out. Any sudden vision changes, headache that won’t quit, or slurred speech mean it’s time to seek urgent care. Liver problems sometimes leave clues like yellowing eyes or skin, dark urine, or pain in the top right side of the stomach.
Estriol can change the way blood clots and can sometimes push up blood pressure. Anyone who already deals with these health issues should talk over estriol’s risks with a healthcare provider.
Research into estriol stretches back decades but hasn’t filled every gap. Some women ask about the risk of cancer, and so far, large studies haven’t shown the spike that comes with other estrogens. Still, no therapy slides by without adding some long-term health questions. Regular health checks—especially pelvic exams, mammograms, and blood pressure readings—help spot concerning changes early.
Anyone on estriol benefits from sharing all health history and medication details with a doctor. Sometimes, lifestyle changes like quitting smoking, staying active, and eating a balanced diet go a long way in lowering risk. Tracking side effects with a journal helps spot patterns. Talking openly at each appointment can flag issues before they spiral.
Doctors sometimes recommend using the lowest helpful dose for the shortest possible time. Some women find relief from symptoms with products applied directly to the skin or vagina, which limits how much hormone gets into the bloodstream.
Facing side effects feels easier with support. Trusted health organizations like the North American Menopause Society and Mayo Clinic give updated, evidence-backed advice. Online communities connect women who share real-life stories and tips. No one needs to figure it all out alone.
Estriol, one of the three main estrogens in the body, shows up in high amounts during pregnancy. Most of the estriol in a pregnant woman's system is made by the placenta. Doctors check estriol levels in blood and urine as part of prenatal screenings, mainly to help spot potential concerns with a baby's development, like Down syndrome or neural tube defects.
Questions about using extra estriol during pregnancy often pop up because of its ties to estrogen therapy and symptoms linked with hormonal changes. Some look to this hormone as a possible solution for vaginal dryness or urinary tract symptoms that strike during pregnancy. It sounds straightforward, but adding hormones to the mix during pregnancy brings a host of questions worth thinking through.
Estriol is not a standard part of pregnancy care. Most guidelines from trusted sources, including the U.S. Food and Drug Administration (FDA) and American College of Obstetricians and Gynecologists (ACOG), do not recommend estriol supplements for pregnant women. There's a good reason for this caution. Estrogen therapy, especially in high doses or strong forms, has links to some birth defects and complications. Research on estriol is less plentiful than for estradiol or conjugated estrogens, but there's not enough evidence to guarantee safety.
Small studies from some countries highlighted estriol's mild nature compared to other estrogens. After all, the body produces it naturally in great amounts during pregnancy. Nevertheless, natural doesn't always mean risk-free. Drug versions come at higher doses and through different delivery methods, not just from the placenta. Medical teams usually stick to the principle of "do no harm" and avoid anything that hasn't shown clear safety.
After giving birth, some mothers consider estrogen-based products, including estriol, for vaginal health or hormone balance. Here, breastfeeding poses its own question. Small levels of estrogen pass into breast milk, and higher total amounts in the body can lower milk supply. Even though estriol counts as a weaker form of estrogen, no strong studies fully clear it of these risks for nursing infants. Evidence points to a cautious path—healthcare professionals rarely, if ever, suggest estriol supplements for lactating mothers.
Having gone through childbirth and decisions about postpartum health, many mothers reevaluate every pill or ointment. The urge to find relief for common struggles, like dryness or discomfort, can be strong, but unchecked supplements sometimes make things worse. Family doctors, midwives, and OB/GYN specialists serve as the first call for questions about estriol or any other hormones in the perinatal period. Sadly, social media and forums often skip safety details, trading in anecdotes instead of science.
Doctors often look for non-hormonal ways to tackle symptoms in pregnancy and breastfeeding. Simple lubricants, hydration, and dietary changes sometimes help more than people expect. For worse troubles, temporary prescription options with long safety records can give peace of mind until nursing ends. Safe choices stem from communicating concerns and having medical teams explain what research shows—and what it still misses.
Estriol’s appeal rests in its reputation for being gentle, but the stakes during pregnancy and breastfeeding urge a more thoughtful pause. Safety for young children and new mothers always deserves the extra step.
Estriol belongs to the family of estrogens, the hormone group that plays a big part in women’s health. Gynecologists often recommend estriol for its milder action compared to other estrogens. Many women start to look for hormone support as they go through menopause. Some turn to estriol for relief from issues like vaginal dryness and painful intercourse. In other countries, you might see estriol used for hormone replacement therapy, either alone or combined with other agents. Estriol creams, tablets, and sometimes even custom-compounded formulas come up in the conversations between women and their healthcare providers more often than you’d think.
In the United States, estriol almost always requires a prescription. The FDA regulates estrogen products strictly because of concerns over safety—especially the possibility of unwanted side effects or the unknown risk profiles in certain women. Other countries vary. In some European countries, a low-dose estriol cream can be bought at a pharmacy without a script. In the UK, for example, some topical forms get dispensed after a chat with the pharmacist, no doctor involved. Still, others like Canada stick closer to the U.S. approach and demand a prescription for all estriol forms, even for local or low-dose use.
Estrogen has a reputation as a helpful and powerful compound. Yet, misuse or unsupervised use brings genuine risks—adverse effects can include blood clots, breast tenderness, or changes in blood pressure. Years working in community pharmacy taught me that self-diagnosis nearly always falls short of safe. Some women experience relief with estriol, but others don't, and a provider can spot subtle signs of trouble or recommend alternatives if needed. Many women think these creams act ‘only locally’ and skip possible systemic impacts. That assumption misses the reality that hormones don’t always stick to one body part. Even local creams sometimes enter the bloodstream, though at a smaller scale.
Many patients grow frustrated with prescription rules. Wait times for doctor visits stretch out, and copays often feel steep, especially for menopausal women seeking comfort with minimal fuss. Online pharmacies have multiplied in recent years, some offering overseas shipment. Some women are tempted by easier access, but safety drops off when unregulated products enter the picture. Purity, dose strength, and ingredient lists come into question—counterfeits and unapproved imports put health on the line.
Policy needs to keep up with real-world needs. One step involves more robust education by doctors and pharmacists. Sharing information about what estriol does, and what signs to watch for, helps people make smarter choices. Expanding access to qualified clinicians, even through telehealth, could also help bridge the frustration gap. In pharmacy, I’ve noticed that counseling changes how a woman uses her medication and the outcomes she gets. Regulators should look at ways to allow limited over-the-counter sales of low-dose estriol—provided strong education and real support remain part of the package. As more women ask about these choices, listening to their lived experience and making safety a priority matters. Buying estriol safely almost always starts with a conversation worth having with someone who knows both the risks and the benefits.
| Names | |
| Preferred IUPAC name | estrea-1,3,5(10)-triene-3,16α,17β-triol |
| Other names |
Oestriol
E3 |
| Pronunciation | /ˈɛstri.ɒl/ |
| Preferred IUPAC name | estra-1,3,5(10)-triene-3,16α,17β-triol |
| Other names |
Ovestin
E3 Estra-1,3,5(10)-triene-3,16α,17β-triol |
| Pronunciation | /ˈɛstri.ɒl/ |
| Identifiers | |
| CAS Number | 50-27-1 |
| Beilstein Reference | 358706 |
| ChEBI | CHEBI:28789 |
| ChEMBL | CHEMBL1537 |
| ChemSpider | 5077 |
| DrugBank | DB04573 |
| ECHA InfoCard | 100.002.942 |
| EC Number | 200-450-5 |
| Gmelin Reference | Gmelin Reference: "166437 |
| KEGG | C01829 |
| MeSH | D004988 |
| PubChem CID | 5756 |
| RTECS number | GO9240000 |
| UNII | 4R4VP6J9Z5 |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID2021986 |
| CAS Number | 50-27-1 |
| 3D model (JSmol) | `/data/mol2/estriol.mol` |
| Beilstein Reference | 1908733 |
| ChEBI | CHEBI:28789 |
| ChEMBL | CHEMBL779 |
| ChemSpider | 5466 |
| DrugBank | DB00854 |
| ECHA InfoCard | 05e6e7d8-b259-4d09-9c93-6c34e2730317 |
| EC Number | 3.1.1.62 |
| Gmelin Reference | Gmelin Reference: **167576** |
| KEGG | C01829 |
| MeSH | D004967 |
| PubChem CID | 5756 |
| RTECS number | KW8225000 |
| UNII | 4V59571OE4 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C18H24O3 |
| Molar mass | 288.381 g/mol |
| Appearance | white or almost white crystalline powder |
| Odor | Odorless |
| Density | 0.4 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 4.01 |
| Vapor pressure | 5.20E-08 mmHg |
| Acidity (pKa) | 10.4 |
| Basicity (pKb) | 4.04 |
| Magnetic susceptibility (χ) | -82.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.604 |
| Viscosity | Viscous liquid |
| Dipole moment | 2.80 D |
| Chemical formula | C18H24O3 |
| Molar mass | 288.381 g/mol |
| Appearance | white or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.36 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.45 |
| Vapor pressure | 2.6 x 10^-8 mmHg |
| Acidity (pKa) | 10.4 |
| Basicity (pKb) | 4.04 |
| Magnetic susceptibility (χ) | -7.6e-6 cm³/mol |
| Refractive index (nD) | 1.578 |
| Dipole moment | 2.78 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 221.0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -920.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4669.2 kJ/mol |
| Std molar entropy (S⦵298) | 355.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -38079 kJ/mol |
| Pharmacology | |
| ATC code | G03CA04 |
| ATC code | G03CA04 |
| Hazards | |
| Main hazards | May damage fertility or the unborn child. |
| GHS labelling | GHS labelling of product 'Estriol': ``` Signal word: Warning Hazard statements: H361d Pictograms: GHS08 ``` |
| Pictograms | 🌐⚠️🚫👶🚺 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P201, P202, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 1-0-0 |
| Flash point | Flash point: 232.2 °C |
| Autoignition temperature | 385 °C |
| Lethal dose or concentration | LD50 (rat, oral): >8000 mg/kg |
| LD50 (median dose) | 6600 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Estriol: Not established |
| REL (Recommended) | Vaginal: 0.5 mg |
| Main hazards | Causes serious eye irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | 💊🔴🚫🤰 |
| Signal word | Warning |
| Hazard statements | H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child. |
| Precautionary statements | P201, P202, P280, P308+P313, P405, P501 |
| Flash point | Flash point: 177.3°C |
| Autoignition temperature | 540 °C |
| Lethal dose or concentration | LD50 (rat, oral): > 5000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Estriol: "4900 mg/kg (rat, oral) |
| NIOSH | RF2 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Estriol: Not established |
| REL (Recommended) | 0.5 mg |
| Related compounds | |
| Related compounds |
Estradiol
Estrone Estrogen 17α-Estradiol Equilin |
| Related compounds |
Estrone
Estradiol Estrogen Ethinylestradiol |
Providing high-quality chemical products and logistics solutions for global trade partners.
